Weekly Research Analysts’ Ratings Changes for Teva Pharmaceutical Industries (TEVA)

A number of firms have modified their ratings and price targets on shares of Teva Pharmaceutical Industries (NYSE: TEVA) recently:

  • 11/23/2022 – Teva Pharmaceutical Industries had its price target lowered by analysts at Piper Sandler from $8.00 to $7.00. They now have an “underweight” rating on the stock.
  • 11/14/2022 – Teva Pharmaceutical Industries was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $10.00 price target on the stock, down previously from $11.00.
  • 11/7/2022 – Teva Pharmaceutical Industries had its price target lowered by analysts at BMO Capital Markets from $11.00 to $10.00. They now have a “market perform” rating on the stock.
  • 11/4/2022 – Teva Pharmaceutical Industries was downgraded by analysts at UBS Group AG from a “neutral” rating to a “sell” rating.
  • 10/21/2022 – Teva Pharmaceutical Industries had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $10.00 price target on the stock.
  • 10/12/2022 – Teva Pharmaceutical Industries is now covered by analysts at StockNews.com. They set a “buy” rating on the stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $8.80 on Friday. The company has a debt-to-equity ratio of 1.94, a current ratio of 0.99 and a quick ratio of 0.66. The company has a market cap of $9.77 billion, a P/E ratio of -7.59 and a beta of 1.27. The stock’s 50-day moving average is $8.54 and its 200 day moving average is $8.63. Teva Pharmaceutical Industries Limited has a 1-year low of $6.78 and a 1-year high of $11.34.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.02). The firm had revenue of $3.60 billion during the quarter, compared to analysts’ expectations of $3.86 billion. Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. Research analysts predict that Teva Pharmaceutical Industries Limited will post 2.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Exor Capital LLP acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $92,984,000. Two Sigma Investments LP raised its stake in shares of Teva Pharmaceutical Industries by 705.1% during the 3rd quarter. Two Sigma Investments LP now owns 5,283,501 shares of the company’s stock worth $42,638,000 after buying an additional 4,627,252 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Teva Pharmaceutical Industries by 23.5% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 14,132,727 shares of the company’s stock valued at $114,051,000 after purchasing an additional 2,685,200 shares in the last quarter. Phoenix Holdings Ltd. increased its stake in Teva Pharmaceutical Industries by 11.8% in the 3rd quarter. Phoenix Holdings Ltd. now owns 20,831,080 shares of the company’s stock valued at $162,941,000 after purchasing an additional 2,201,291 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $15,342,000. Hedge funds and other institutional investors own 46.22% of the company’s stock.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Featured Stories

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.